AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21567070 — intervention group
Group type: EXPERIMENTAL
Intervention: sivelestat (0.2 mg/kg/h from induction of anesthesia to post-operative day 1)
Number of subjects: 24
Study 21567070 — intervention group
Group type: COMPARATOR
Intervention: physiological saline (control group)
Number of subjects: 24
Study 19506392 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (1.3, 2.0, and 2.7 mg/m(2)/day)
Number of subjects: 39
Study 17034608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 1 week before PCNL
Number of subjects: 115
Study 17034608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ciprofloxacin)
Number of subjects: 115
Study 15328756 — intervention group
Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort)
Number of subjects: 48
Study 15328756 — intervention group
Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort) 2 active capsules per day
Number of subjects: 48
Study 15328756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15328756 — intervention group
Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort) 3 capsules per day
Number of subjects: 48
Study 11002713 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of alfentanil at T5-7 (group T)
Number of subjects: 30
Study 11002713 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of alfentanil at L2-3 (group L)
Number of subjects: 30
Study 9149197 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 35% CO2
Number of subjects: 14
Study 9149197 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 14
Study 9149197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensilon 10 mg i.v.
Number of subjects: 14
Study 8450060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib PS-OMPC
Number of subjects: 0
Study 8450060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo-CRM
Number of subjects: 0
Study 8450060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib PS-T
Number of subjects: 0
Study 3766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoscanate 3.5 mg/kg
Number of subjects: 12
Study 3766854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoscanate 1 mg/kg
Number of subjects: 12
Study 3766854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30354784 — intervention group
Group type: COMPARATOR
Intervention: BNS (Misago stent implantation without cilostazol)
Number of subjects: 255
Study 30354784 — intervention group
Group type: EXPERIMENTAL
Intervention: BNS with cilostazol (Misago stent implantation with cilostazol)
Number of subjects: 255
Study 30354784 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (Zilver PTX stent implantation without cilostazol)
Number of subjects: 255
Study 27566622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 90
Study 27566622 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 90
Study 27566622 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25566620 — intervention group
Group type: EXPERIMENTAL
Intervention: Yindan Xinnaotong Soft Capsule (YXSC)
Number of subjects: 118
Study 25566620 — intervention group
Group type: COMPARATOR
Intervention: Naoxintong Capsule (NC)
Number of subjects: 118
Study 21960068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol-fixed combination (DTFC)
Number of subjects: 60
Study 21960068 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine/timolol-fixed combination (BTFC)
Number of subjects: 60
Study 20156345 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (two specifically tailored supervised moderate intensity aerobic exercise sessions weekly over 8 weeks)
Number of subjects: 64
Study 20156345 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 18215592 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 180
Study 18215592 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 180
Study 18215592 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 180
Study 18215592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 180
Study 18215592 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors or clopidogrel
Number of subjects: 180
Study 15730347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg twice daily (n = 34)
Number of subjects: 69
Study 15730347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 69
Study 14607207 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 mg once daily
Number of subjects: 305
Study 14607207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 10685831 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 0
Study 10685831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 9124201 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE plus 5'-DFUR (400 mg/day)
Number of subjects: 40
Study 9124201 — intervention group
Group type: COMPARATOR
Intervention: TAE alone
Number of subjects: 40
Study 9124201 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE plus 5'-DFUR
Number of subjects: 40
Study 8087578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation treatment modalities
Number of subjects: 0
Study 8087578 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment protocols
Number of subjects: 0
Study 3098543 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 0
Study 3098543 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral PKP
Number of subjects: 178
Study 31564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral PKP
Number of subjects: 178
Study 27896528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (660 ± 20 nm, 3 J/cm2) along with conventional therapy
Number of subjects: 30
Study 27896528 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 30
Study 24135258 — intervention group
Group type: EXPERIMENTAL
Intervention: Manager trained
Number of subjects: 42
Study 24135258 — intervention group
Group type: EXPERIMENTAL
Intervention: Manager and staff trained
Number of subjects: 42
Study 24135258 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 42
Study 23269370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-access laparoscopic cholecystectomy (SALC)
Number of subjects: 269
Study 23269370 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 269
Study 21539702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal injection of steroids (TFIS)
Number of subjects: 71
Study 18298236 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback intervention (PFI)
Number of subjects: 230
Study 18298236 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed feedback intervention (PFI)
Number of subjects: 230
Study 17038949 — intervention group
Group type: COMPARATOR
Intervention: Narcotics alone (Control)
Number of subjects: 27
Study 17038949 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor in addition to narcotics (Experimental)
Number of subjects: 27
Study 14522292 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% dye (Blurhex) used in Group 2
Number of subjects: 42
Study 14522292 — intervention group
Group type: COMPARATOR
Intervention: No trypan blue dye used in Group 1
Number of subjects: 42
Study 10768304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 743
Study 10768304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 10 Hz, cosine phase, modulation index varied
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 10 Hz, cosine phase, fixed modulation index m at 0.5, roved background harmonic levels
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 10 Hz, random phase
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 2 Hz, cosine phase, all formants modulated in phase
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 2 Hz, random phase
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 2 Hz, randomizing level of each background harmonic
Number of subjects: 0
Study 8730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude modulation (AM) at or close to 2 Hz, differing phase across formants
Number of subjects: 0
Study 1804649 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 33557 (100 mg)
Number of subjects: 6
Study 1804649 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 33557 (300 mg)
Number of subjects: 6
Study 1804649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6342980 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc pyrithione shampoo
Number of subjects: 40
Study 6342980 — intervention group
Group type: COMPARATOR
Intervention: Shampoo base
Number of subjects: 40
Study 31693879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (SGLT2 inhibitor)
Number of subjects: 0
Study 31693879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29202563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hyaluronic acid (HA) via Spray-sol, twice a day for 10 days (T1)
Number of subjects: 25
Study 29202563 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline nebulized via Spray-sol, twice a day for 10 days (T2)
Number of subjects: 25
Study 25370359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary support (D)
Number of subjects: 192
Study 25370359 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-exercise program (E)
Number of subjects: 192
Study 25370359 — intervention group
Group type: COMPARATOR
Intervention: No attention (C)
Number of subjects: 192
Study 24326281 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 515
Study 24326281 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 515
Study 23559924 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (Kerr, USA)
Number of subjects: 12
Study 23559924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray, Japan) with enamel etching
Number of subjects: 12
Study 23559924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol wet bonding technique with part of adhesive of OptiBond FL
Number of subjects: 12
Study 23559924 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 19668121 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 50 mg/day
Number of subjects: 723
Study 19668121 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/day
Number of subjects: 723
Study 19668121 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day
Number of subjects: 723
Study 19668121 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 723
Study 17602036 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (bolus and infusion before cardiopulmonary bypass until skin closure)
Number of subjects: 50
Study 17602036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15369795 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16-positive women
Number of subjects: 197
Study 15369795 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16-positive women with CIN 3 or invasive cancer
Number of subjects: 197
Study 12365907 — intervention group
Group type: COMPARATOR
Intervention: Standard AcrySof MA30 intraocular lens (group 1)
Number of subjects: 60
Study 12365907 — intervention group
Group type: EXPERIMENTAL
Intervention: MA30 intraocular lens with a textured optic edge (group 2)
Number of subjects: 60
Study 12365907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 9833595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 32
Study 9833595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 32
Study 9833595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg after food
Number of subjects: 32
Study 9833595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all doses)
Number of subjects: 32
Study 8566267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile administration of hMG
Number of subjects: 88
Study 8566267 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of hMG
Number of subjects: 88
Study 2081896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg)
Number of subjects: 34
Study 2081896 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (150 mg)
Number of subjects: 34
Study 7428356 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estrogen product (4mg estradiol + 2mg estriol)
Number of subjects: 925
Study 7428356 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol product (50 microgram ethinyl estradiol)
Number of subjects: 925
Study 7428356 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estrogen product
Number of subjects: 925
Study 7428356 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol product
Number of subjects: 925
Study 7428356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 925
Study 30953792 — intervention group
Group type: EXPERIMENTAL
Intervention: NTproBNP measured at baseline, 48-72 hours, and 30 days
Number of subjects: 795
Study 30953792 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative changes in NTproBNP
Number of subjects: 795
Study 30953792 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute and relative changes in NTproBNP from baseline to 48-72 hours and to 30 days
Number of subjects: 795
Study 30953792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable models with relative and absolute change in NTproBNP
Number of subjects: 795
Study 28372555 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff educational programme delivered by the team of researchers
Number of subjects: 28
Study 28372555 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study 26413500 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg DHA supplementation
Number of subjects: 871
Study 26413500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 871
Study 26413500 — intervention group
Group type: COMPARATOR
Intervention: Combined DHA supplementation (300 and 600 mg/day)
Number of subjects: 871
Study 26413500 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC DHA increase
Number of subjects: 871
Study 26413500 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 871
Study 25168665 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d + Pregabalin 300 mg/d
Number of subjects: 0
Study 25168665 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 0
Study 25168665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination/high-dose therapy
Number of subjects: 0
Study 25168665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose monotherapy
Number of subjects: 0
Study 25168665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 22862951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 498
Study 22862951 — intervention group
Group type: COMPARATOR
Intervention: Non-Pringle group
Number of subjects: 498
Study 20704667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with parameters: wavelength 905 nm, frequency 5,000 Hz, power density of 12 mW/cm², dose of 2 J/cm², treatment time 120 seconds, total dose 12 J/cm²
Number of subjects: 60
Study 20704667 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure (inactive laser)
Number of subjects: 60
Study 17654276 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic intrusions
Number of subjects: 0
Study 17654276 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset intrusions
Number of subjects: 0
Study 17654276 — intervention group
Group type: COMPARATOR
Intervention: Rhyme intrusions
Number of subjects: 0
Study 16295700 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity e-mail-based walking program
Number of subjects: 61
Study 16295700 — intervention group
Group type: COMPARATOR
Intervention: Low fidelity e-mail-based walking program
Number of subjects: 61
Study 11864673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum epidural analgesia
Number of subjects: 116
Study 10651664 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 246
Study 10651664 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 246
Study 10651664 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 246
Study 10651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment metronidazole resistance
Number of subjects: 246
Study 8554362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape recorded summary
Number of subjects: 113
Study 2403655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g intravenously) administered approximately half an hour before surgery
Number of subjects: 1218
Study 2403655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 1218
Study 331920 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 24 mg daily
Number of subjects: 53
Study 331920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31944221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (80 mg/m2 daily)
Number of subjects: 189
Study 31944221 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (300 mg/m2 daily)
Number of subjects: 189
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Land use types within a 500 m buffer zone
Number of subjects: 30
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Land use types within a 1 km buffer zone
Number of subjects: 30
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Built‐up land
Number of subjects: 30
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmland
Number of subjects: 30
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivers within a 200 m buffer zone
Number of subjects: 30
Study 31854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of lake area
Number of subjects: 30
Study 27965045 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 36
Study 27965045 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Treatment (BMT)
Number of subjects: 36
Study 25321162 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% mannitol
Number of subjects: 124
Study 25321162 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% mannitol + 10 mg scopolamine butylbromide
Number of subjects: 124
Study 25321162 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% mannitol + 20 mg scopolamine butylbromide
Number of subjects: 124
Study 25321162 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 124
Study 23837833 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement strategy tailored to barriers and facilitators
Number of subjects: 19
Study 23837833 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy of audit and feedback
Number of subjects: 19
Study 22057498 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPH-PDT with 3 mg/m2 HPPH plus 175 J/cm light
Number of subjects: 36
Study 22057498 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPH-PDT with 4 mg/m2 HPPH plus 150 J/cm light
Number of subjects: 36
Study 22057498 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPH-PDT with 3 mg/m2 HPPH (light dose of 150 J/cm at 48 hours)
Number of subjects: 36
Study 22057498 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPH-PDT with 4 mg/m2 HPPH (light dose at 24 hours)
Number of subjects: 36
Study 22057498 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPH-PDT
Number of subjects: 36
Study 18958483 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy and immediate oxytocin infusion
Number of subjects: 123
Study 18958483 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy and delayed oxytocin infusion
Number of subjects: 123
Study 16775166 — intervention group
Group type: EXPERIMENTAL
Intervention: History of injecting drug use
Number of subjects: 694
Study 16775166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus infection
Number of subjects: 694
Study 16775166 — intervention group
Group type: COMPARATOR
Intervention: Sexually transmitted infections, sexual behavior, blood transfusions, influenza, acne, occupational or domestic exposure to zoonotic infections
Number of subjects: 694
Study 15565373 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide + Metformin
Number of subjects: 118
Study 15565373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 118
Study 15565373 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 118
Study 12964326 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Four high compression bandage system
Number of subjects: 50
Study 12964326 — intervention group
Group type: COMPARATOR
Intervention: Earlier evaluated bandages (including the original Charing Cross system)
Number of subjects: 50